MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis

Stem Cells

Volumn 29, Issue 12, 2011, Pages 1942-1951

  Sato, Atsushi ^a   Sunayama, Jun ^a,b,c   Matsuda, Ken Ichiro ^a   Seino, Shizuka ^a,b,c   Suzuki, Kaori ^a,b,c   Watanabe, Eriko ^a,b,c   Tachibana, Ken ^a   Tomiyama, Arata ^a   Kayama, Takamasa ^a   Kitanaka, Chifumi ^a,b,c  

^a YAMAGATA UNIVERSITY   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

^c JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

Author keywords

Cancer stem cell; Chemoresistance; Combination therapy; Glioma; Mitogen activated protein kinase

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ALPHA [AMINO(4 AMINOPHENYLTHIO)METHYLENE] 2 (TRIFLUOROMETHYL)PHENYLACETONITRILE; DNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN MDM2; PROTEIN P53; TEMOZOLOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER RESISTANCE; CONTROLLED STUDY; DNA REPAIR; DOWN REGULATION; ENZYME INHIBITION; GENE EXPRESSION; GENE TARGETING; GLIOBLASTOMA; MALE; MOUSE; NONHUMAN; UPREGULATION;

AMINOACETONITRILE; ANIMALS; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; IMIDAZOLES; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; RNA INTERFERENCE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

MURINAE;

EID: 81855206186     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.753     Document Type: Article

References (38)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359:492-507.
2. Khasraw M, Lassman AB. Advances in the treatment of malignant gliomas. Curr Oncol Rep 2010;12:26-33.
3. Villano JL, Seery TE, Bressler LR. Temozolomide in malignant gliomas: Current use and future targets. Cancer Chemother Pharmacol 2009;64:647-655.
4. Nishikawa R. Standard therapy for glioblastoma - A review of where we are. Neurol Med Chir (Tokyo) 2010;50:713-719.
5. Hegi ME, Liu L, Herman JG et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008;26:4189-4199.
6. Hermisson M, Klumpp A, Wick W et al. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 2006;96:766-776.
7. Blough MD, Westgate MR, Beauchamp D et al. Sensitivity to temozolomide in brain tumor initiating cells. Neuro Oncol 2010;12:756-760.
8. Spiegl-Kreinecker S, Pirker C, Filipits M et al. O6-methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. Neuro Oncol 2010;12:28-36.
9. Kato T, Natsume A, Toda H et al. Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells. Gene Ther 2010;17:1363-1371.
10. Lee J, Kotliarova S, Kotliarov Y et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006;9:391-403. (Pubitemid 43668737)
11. Schulte A, Gunther HS, Phillips HS et al. A distinct subset of glioma cell lines with stem cell-like properties reflects the transcriptional phenotype of glioblastomas and overexpresses CXCR4 as therapeutic target. Glia 2011;59:590-602.
12. Neman J, Jandial R. Decreasing glioma recurrence through adjuvant cancer stem cell inhibition. Biologics 2010;4:157-162.
13. Clevers H. The cancer stem cell: Premises, promises and challenges. Nat Med 2011;17:313-319.
14. Sunayama J, Matsuda K, Sato A et al. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of selfrenewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells 2010;28:1930-1939.
15. Pollard SM, Yoshikawa K, Clarke ID et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 2009;4: 568-580.
16. Fael Al-Mayhani TM, Ball SL, Zhao JW et al. An efficient method for derivation and propagation of glioblastoma cell lines that conserves the molecular profile of their original tumours. J Neurosci Methods 2009;176:192-199.
17. Ikushima H, Todo T, Ino Y et al. Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell 2009;5:504-514.
18. Ostermann S, Csajka C, Buclin T et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004;10:3728-3736. (Pubitemid 38697606)
19. Liu G, Yuan X, Zeng Z et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006;5:67.
20. Harris LC, Remack JS, Houghton PJ et al. Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene. Cancer Res 1996;56:2029-2032. (Pubitemid 26119903)
21. Grombacher T, Eichhorn U, Kaina B. p53 is involved in regulation of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents. Oncogene 1998;17:845-851. (Pubitemid 28430207)
22. Srivenugopal KS, Shou J, Mullapudi SR et al. Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents. Clin Cancer Res 2001;7:1398-1409. (Pubitemid 32708697)
23. Bocangel D, Sengupta S, Mitra S et al. p53-mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor. Anticancer Res 2009;29:3741-3750.
24. Hock A, Vousden KH. Regulation of the p53 pathway by ubiquitin and related proteins. Int J Biochem Cell Biol 2010;42:1618-1621.
25. Shangary S, Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: A novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 2009;49: 223-241.
26. Ries S, Biederer C, Woods D et al. Opposing effects of Ras on p53: Transcriptional activation of mdm2 and induction of p19ARF. Cell 2000;103:321-330.
27. Phelps M, Phillips A, Darley M et al. MEK-ERK signaling controls Hdm2 oncoprotein expression by regulating hdm2 mRNA export to the cytoplasm. J Biol Chem 2005;280:16651-16658. (Pubitemid 41389122)
28. Shamsara J, Sharif S, Afsharnezhad S et al. Association between MGMT promoter hypermethylation and p53 mutation in glioblastoma. Cancer Invest 2009;27:825-829.
29. Groenendijk FH, Taal W, Dubbink HJ et al. MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation. J Neurooncol 2011;101:405-417.
30. Network TCGAR. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-1068.
31. Blough MD, Beauchamp DC, Westgate MR et al. Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma. J Neurooncol 2011; 102:1-7.
32. Ernst A, Hofmann S, Ahmadi R et al. Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. Clin Cancer Res 2009;15:6541-6550.
33. Beier D, Rohrl S, Pillai DR et al. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 2008;68:5706-5715.
34. Koch D, Hundsberger T, Boor S et al. Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma. J Neurooncol 2007;82:85-89.
35. Feldkamp MM, Lala P, Lau N et al. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 1999;45:1442-1453.
36. Lopez-Gines C, Gil-Benso R, Benito R et al. The activation of ERK1/2 MAP kinases in glioblastoma pathobiology and its relationship with EGFR amplification. Neuropathology 2008;28:507-515.
37. Natsume A, Ishii D, Wakabayashi T et al. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res 2005;65:7573-7579. (Pubitemid 41297227)
38. Bobustuc GC, Baker CH, Limaye A et al. Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro Oncol 2010;12:917-927.